Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial

Amit C. Achhra; Amanda Mocroft; Michael Ross; Lene Ryom-Nielson; Anchalee Avihingsanon; Elzbieta Bakowska; Waldo Belloso; Amanda Clarke; Hansjakob Furrer; Gregory M. Lucas; Matti Ristola; Mohammed Rassool; Jonathan Ross; Charurut Somboonwit; Shweta Sharma; Christina Wyatt

doi:10.1016/j.ijantimicag.2017.04.021

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial

Amit C. Achhra^*, Amanda Mocroft, Michael Ross, Lene Ryom-Nielson, Anchalee Avihingsanon, Elzbieta Bakowska, Waldo Belloso, Amanda Clarke, Hansjakob Furrer, Gregory M. Lucas, Matti Ristola, Mohammed Rassool, Jonathan Ross, Charurut Somboonwit, Shweta Sharma, Christina Wyatt

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

21 Citations (SciVal)

Original language	English
Pages (from-to)	453-460
Number of pages	8
Journal	International Journal of Antimicrobial Agents
Volume	50
Issue number	3
DOIs	https://doi.org/10.1016/j.ijantimicag.2017.04.021
Publication status	Published (VoR) - Sept 2017

Keywords

CKD
HAART
HIV
Kidney
START
eGFR

Access to Document

10.1016/j.ijantimicag.2017.04.021

Cite this

Achhra, A. C., Mocroft, A., Ross, M., Ryom-Nielson, L., Avihingsanon, A., Bakowska, E., Belloso, W., Clarke, A., Furrer, H., Lucas, G. M., Ristola, M., Rassool, M., Ross, J., Somboonwit, C., Sharma, S., & Wyatt, C. (2017). Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. International Journal of Antimicrobial Agents, 50(3), 453-460. https://doi.org/10.1016/j.ijantimicag.2017.04.021

@article{588c4d4041d840bb9b24359549a0911d,

title = "Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial",

keywords = "CKD, HAART, HIV, Kidney, START, eGFR",

author = "Achhra, {Amit C.} and Amanda Mocroft and Michael Ross and Lene Ryom-Nielson and Anchalee Avihingsanon and Elzbieta Bakowska and Waldo Belloso and Amanda Clarke and Hansjakob Furrer and Lucas, {Gregory M.} and Matti Ristola and Mohammed Rassool and Jonathan Ross and Charurut Somboonwit and Shweta Sharma and Christina Wyatt",

note = "Funding Information: Funding: This work was supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases [UM1 AI 068641, UM1-AI120197]; the Department of Bioethics at the NIH Clinical Center; the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; and the National Institute of Arthritis and Musculoskeletal Disorders. Financial support for START was also provided by the French Agence Nationale de Recherches sur le SIDA et les H?patites Virales (ANRS); the Federal Ministry of Education and Research; the European AIDS Treatment Network (NEAT); the National Health and Medical Research Council; and the Medical Research Council and National Institute for Health Research. Six pharmaceutical companies (AbbVie, Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, LLC, and Merck Sharp and Dohme Corp.) donate antiretroviral drugs to START. The authors were also supported by the National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK100272, P01 DK056492 and R01 DK112258 to CW] and the National Institute on Drug Abuse [K24 DA035684, R01 DA026770 to GML]. Publisher Copyright: {\textcopyright} 2017 Elsevier B.V. and International Society of Chemotherapy",

year = "2017",

month = sep,

doi = "10.1016/j.ijantimicag.2017.04.021",

language = "English",

volume = "50",

pages = "453--460",

journal = "International Journal of Antimicrobial Agents",

issn = "0924-8579",

publisher = "Elsevier",

number = "3",

}

Achhra, AC, Mocroft, A, Ross, M, Ryom-Nielson, L, Avihingsanon, A, Bakowska, E, Belloso, W, Clarke, A, Furrer, H, Lucas, GM, Ristola, M, Rassool, M, Ross, J, Somboonwit, C, Sharma, S & Wyatt, C 2017, 'Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial', International Journal of Antimicrobial Agents, vol. 50, no. 3, pp. 453-460. https://doi.org/10.1016/j.ijantimicag.2017.04.021

TY - JOUR

T1 - Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial

AU - Achhra, Amit C.

AU - Mocroft, Amanda

AU - Ross, Michael

AU - Ryom-Nielson, Lene

AU - Avihingsanon, Anchalee

AU - Bakowska, Elzbieta

AU - Belloso, Waldo

AU - Clarke, Amanda

AU - Furrer, Hansjakob

AU - Lucas, Gregory M.

AU - Ristola, Matti

AU - Rassool, Mohammed

AU - Ross, Jonathan

AU - Somboonwit, Charurut

AU - Sharma, Shweta

AU - Wyatt, Christina

N1 - Funding Information: Funding: This work was supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases [UM1 AI 068641, UM1-AI120197]; the Department of Bioethics at the NIH Clinical Center; the National Cancer Institute; the National Heart, Lung, and Blood Institute; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; and the National Institute of Arthritis and Musculoskeletal Disorders. Financial support for START was also provided by the French Agence Nationale de Recherches sur le SIDA et les H?patites Virales (ANRS); the Federal Ministry of Education and Research; the European AIDS Treatment Network (NEAT); the National Health and Medical Research Council; and the Medical Research Council and National Institute for Health Research. Six pharmaceutical companies (AbbVie, Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, LLC, and Merck Sharp and Dohme Corp.) donate antiretroviral drugs to START. The authors were also supported by the National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK100272, P01 DK056492 and R01 DK112258 to CW] and the National Institute on Drug Abuse [K24 DA035684, R01 DA026770 to GML]. Publisher Copyright: © 2017 Elsevier B.V. and International Society of Chemotherapy

PY - 2017/9

Y1 - 2017/9

KW - CKD

KW - HAART

KW - HIV

KW - Kidney

KW - START

KW - eGFR

UR - http://www.scopus.com/inward/record.url?scp=85027254683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027254683&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2017.04.021

DO - 10.1016/j.ijantimicag.2017.04.021

M3 - Article

C2 - 28668686

AN - SCOPUS:85027254683

SN - 0924-8579

VL - 50

SP - 453

EP - 460

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 3

ER -

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial

Keywords

Access to Document

Other files and links

Fingerprint

Cite this